Less than two weeks to go!  We hope you share our enthusiasm for this exciting new branch of medicine.  To keep in line with our previous postings, this week we would like to again highlight one of speakers.  This time we have given the nod to an equine surgeon, Dr. Wes Sutter…

Dr. Sutter was and raised born in Lander, Wyoming.  He received his bachelors of science in biochemistry from Colorado State University in 1997.  He then completed his doctor of veterinary medicine from Colorado State University in 2000.  Following veterinary school he completed a one-year rotating equine surgery and medicine internship at Rood and Riddle Equine Hospital in Lexington, Kentucky.  He then completed a surgical residency at The Ohio State University where he later served as an assistant professor in equine orthopedic surgery before entering private practice as a surgeon at Ocala Equine Hospital.  After 5 years at Ocala Equine Hospital in 2010 he co-founded Lexington Equine Surgery and Sports Medicine in Lexington Kentucky. While in practice, he has authored several peer-reviewed publications, book chapters and editorials. His primary clinical focus is orthopedic surgery and sports medicine.

Dr. Sutter likely has more experience with platelet rich plasma (PRP) than any other veterinarian in North America and this will be the focus of his presentation in Manhattan – while his experience is with horses, his lecture will be directly applicable to many small animal indications.  Here is an abstract from one of Dr. Sutter’s papers:

J Am Vet Med Assoc. 2008 May 15;232(10):1515-20. doi: 10.2460/javma.232.10.1515.

Intralesional injection of platelet-rich plasma followed by controlled exercise for treatment of midbody suspensory ligament desmitis in Standardbred racehorses.

Waselau M1Sutter WWGenovese RLBertone AL.

Author information

  • 1Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, OH 43210, USA.



To determine outcome of Standardbred racehorses with moderate to severe midbody suspensory ligament desmitis (MSD) treated by means of ultrasound-guided intralesional injection of a single dose of platelet-rich plasma (PRP) followed by a program of gradually increased exercise.


Nonrandomized clinical trial.


9 Standardbred racehorses.


Following injection of PRP, horses were allowed a controlled, gradual return to exercise. Race records for the year prior to injury and for 3 consecutive years after horses returned to racing were reviewed. For comparison purposes, race records of 9 Standardbred racehorses with no history of MSD racing at the same time were also reviewed.


All 9 horses with MSD returned to racing after treatment; median time to return to racing was 32 weeks. All 9 horses raced at least once during the first and second years after returning to racing, but only 5 raced during the third year. When number of starts, total earnings, and earnings per start were compared between case and comparison horses, the only significant differences were number of starts during the third year after case horses returned to racing and earnings per start during the first year after case horses returned to racing, with values being significantly lower for case horses than for comparison horses.


Results suggested that horses with moderate to severe MSD treated by means of intralesional injection of a single dose of PRP followed by a program of gradually increased exercise had an excellent prognosis for returning to racing.

Looking forward to seeing you all in Manhattan!

Best regards,